Hengrui Pharma
Coverage of Hengrui Pharma in the Nexus archive.
- Moolenaar Calls to Restrict American Investment in China’s Biotechnology Companies
Chairman John Moolenaar of the Select Committee on China urged Treasury Secretary Scott Bessent to add biotechnology to the prohibited technologies list under the COINS Act of 2025. The request follows increased American investment and intellectual property transfers to China’s biotechnology sector, including Bristol Myers Squibb’s $15 billion deal with Hengrui Pharma.
- STAT+: Hims’ sales miss as telehealth competition grows
Rigel Pharma will market the newly approved breast cancer drug Veppanu, while Roche received European clearance for a new blood test to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1. Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs.
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
Bristol Myers Squibb has partnered with Hengrui Pharma on over a dozen early-stage programs, including a $600 million upfront payment and a potential value of up to $15.2 billion. The deal grants Bristol rights to four Hengrui drug candidates outside of mainland China, Hong Kong, and Macau. Hengrui will commercialize four immunology drugs from Bristol in the region.